Clinical Trial Update: First Study in Humans With GSK424887 [Phase 1]

View source ↗

Summary

GlaxoSmithKline's GSK424887 completed its first-in-human Phase 1 trial in individuals with depressive and anxiety disorders.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anxiety Disorders
• Major Depressive Disorder

Drugs mentioned

• GSK424887

Snippet

Sponsor: GlaxoSmithKline | Conditions: Depressive Disorder and Anxiety Disorders | Phase 1 | Status: COMPLETED